847 related articles for article (PubMed ID: 31064193)
1. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
2. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
[TBL] [Abstract][Full Text] [Related]
4. Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
Zhu Y; Wang J; Wang F; Yan Z; Liu G; Ma Y; Zhu W; Li Y; Xie L; Bazhin AV; Guo X
Biochemistry (Mosc); 2019 May; 84(5):575-582. PubMed ID: 31234772
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection.
Gablo N; Trachtova K; Prochazka V; Hlavsa J; Grolich T; Kiss I; Srovnal J; Rehulkova A; Lovecek M; Skalicky P; Berindan-Neagoe I; Kala Z; Slaby O
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32751582
[TBL] [Abstract][Full Text] [Related]
8. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
[TBL] [Abstract][Full Text] [Related]
9. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma.
Harada T; Uemura K; Sumiyoshi T; Shintakuya R; Okada K; Hara T; Takahashi S; Hiyama E
Pancreatology; 2023 Dec; 23(8):996-1002. PubMed ID: 37945497
[TBL] [Abstract][Full Text] [Related]
12. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
[TBL] [Abstract][Full Text] [Related]
13. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
Ling Q; Xu X; Ye P; Xie H; Gao F; Hu Q; Liu Z; Wei X; Röder C; Trauzold A; Kalthoff H; Zheng S
Oncotarget; 2017 Feb; 8(9):15159-15167. PubMed ID: 28122349
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Next Generation Sequencing in Analysis of Circulating MicroRNAs as Predictive Biomarkers for Patients with Locally Advanced Rectal Carcinoma.
Macháčková T; Grolich T; Fiala L; Procházka V; Škrovina M; Kala Z; Slabý O
Klin Onkol; 2019; 32(Supplementum1):157-159. PubMed ID: 31064188
[TBL] [Abstract][Full Text] [Related]
15. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
17. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
Karásek P; Hermanová M
Klin Onkol; 2016; 29(5):336-341. PubMed ID: 27739311
[TBL] [Abstract][Full Text] [Related]
19. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]